{
    "clinical_study": {
        "@rank": "11681", 
        "arm_group": {
            "arm_group_label": "SPN-810M", 
            "arm_group_type": "Experimental", 
            "description": "Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 \u00b5Ci) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 \u00b5Ci) [14C] SPN-810M."
        }, 
        "brief_summary": {
            "textblock": "An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and\n      Excretion of Radio Labeled SPN-810M in Healthy Adult Male Volunteers."
        }, 
        "brief_title": "Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M.", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Impulsive Aggression Comorbid With ADHD", 
        "condition_browse": {
            "mesh_term": "Aggression"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Entry:\n\n          1. Healthy males.\n\n          2. Aged 30 to 55 years.\n\n          3. Considered medically healthy by the Investigator via assessment of physical\n             examination, medical history, clinical laboratory tests, urinalysis, vital signs, and\n             electrocardiogram.\n\n          4. Able to voluntarily provide written informed consent to participate in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "7", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023606", 
            "org_study_id": "810P111"
        }, 
        "intervention": {
            "arm_group_label": "SPN-810M", 
            "intervention_name": "SPN-810M", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Impulsive Aggression , ADHD", 
        "lastchanged_date": "December 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ruddington", 
                    "country": "United Kingdom", 
                    "state": "Nottingham", 
                    "zip": "NG11 6JS"
                }, 
                "name": "Quotient Clinical"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion (AME) of [14C] Labeled SPN-810M in Healthy Adult Male Volunteers.", 
        "overall_official": {
            "affiliation": "Quotient Clinical", 
            "last_name": "Jo Collier, MBChB", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "C(urine and feces), Ae(urine and feces), CumAe(urine and feces), % Dose(urine and feces), CUM% Dose(urine and feces).", 
            "measure": "Urinary and fecal recoveries (mass balance) of total radioactivity.", 
            "safety_issue": "No", 
            "time_frame": "10 days post dose."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023606"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To determine whole blood and plasma partitioning of total radioactivity", 
                "measure": "Whole blood and plasma partitioning of total radioactivity.", 
                "safety_issue": "No", 
                "time_frame": "10 days post dose."
            }, 
            {
                "description": "PK of total radioactivity in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).", 
                "measure": "Pharmacokinetics (PK) of total radioactivity in plasma.", 
                "safety_issue": "No", 
                "time_frame": "10 days post dose."
            }, 
            {
                "description": "PK of SPN-810 in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).", 
                "measure": "PK of SPN-810 in plasma.", 
                "safety_issue": "No", 
                "time_frame": "10 days post dose."
            }, 
            {
                "description": "PK of the major metabolites of SPN-810 in plasma (Cmax, Tmax, AUC0-t, AUCinf, Kel, and t1/2).", 
                "measure": "PK of the major metabolites of SPN-810 in plasma.", 
                "safety_issue": "No", 
                "time_frame": "10 days post dose."
            }, 
            {
                "description": "To characterize and identify the metabolites of SPN-810 in plasma, urine and feces.", 
                "measure": "Metabolites of SPN-810 in plasma, urine and feces", 
                "safety_issue": "No", 
                "time_frame": "10 days post dose."
            }, 
            {
                "description": "To assess the safety and tolerability of SPN-810 by collecting Adverse Events.", 
                "measure": "Safety and tolerability of SPN-810.", 
                "safety_issue": "Yes", 
                "time_frame": "10 days post dose."
            }
        ], 
        "source": "Supernus Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Supernus Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}